Dividends Inside 
AbbVie Inc.
ABBV
$261.07 (+ $10.01 + 3.99%)
Last updated: 2026-07-04 03:24 UTC
AbbVie Inc. trades under ticker ABBV on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US00287Y1091, CUSIP 00287Y109.
About the Company
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheumatology, gastroenterology, dermatology, and related areas. In oncology, it provides therapies such as Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis targeting blood cancers, lymphoma, and lung cancer. AbbVie Inc. also addresses virology with Mavyret for hepatitis C, neuroscience for neurological disorders like Parkinson's, and additional areas including metabolic diseases, cystic fibrosis complications, endometriosis pain, irritable bowel syndrome, chronic constipation, and pancreatic enzyme therapy with Creon, alongside aesthetics products like Botox and Linzess/Constella. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. plays a vital role in the healthcare sector by delivering solutions for complex, chronic, and serious health conditions.
Price History
Latest News for ABBV
Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff”
We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. AbbVie Inc. (NYSE:ABBV) is one of the stocks discussed by Jim Cramer. Pharmaceutical firm AbbVie Inc. (NYSE:ABBV)’s shares are up by 11% over the past year and are down by 9% year-to-date. Evercore ISI was out with optimistic coverage […]
2 Cash-Producing Stocks to Research Further and 1 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc. (NYSE:ABBV) received a rating update from Evercore ISI on May 4, with the firm lifting the price target on the stock to $236 from $232 while maintaining an Outperform rating on the shares. The company also announced […]
Top Stock Reports for NVIDIA, Mastercard & AbbVie
NVIDIA, Mastercard and AbbVie headline Zacks' top stock reports, with AI growth, payment trends and drug launches in focus.